Patents by Inventor Ulrik Wahlberg

Ulrik Wahlberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 9314502
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 19, 2016
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20160045564
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 26, 2015
    Publication date: February 18, 2016
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY
    Publication number: 20150335587
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Application
    Filed: August 7, 2015
    Publication date: November 26, 2015
    Inventors: Philip KUSK, Lars Ulrik WAHLBERG
  • Cell lines and their use in encapsulated cell biodelivery
    Patent number: 9121037
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: September 1, 2015
    Assignee: NsGene A/S
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Treatment of Allodynia, Hyperalgsia, Spontaneous Pain, and Phantom Pain
    Publication number: 20150231208
    Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.
    Type: Application
    Filed: September 5, 2012
    Publication date: August 20, 2015
    Applicant: NSGENE A/S
    Inventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN
    Publication number: 20150202262
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Application
    Filed: August 22, 2014
    Publication date: July 23, 2015
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 9068015
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 30, 2015
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY
    Publication number: 20140377341
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 25, 2014
    Applicant: NsGene A/S
    Inventors: Philip KUSK, Lars Ulrik Wahlberg
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 8815810
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 26, 2014
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Cell lines and their use in encapsulated cell biodelivery
    Patent number: 8741340
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: June 3, 2014
    Assignee: NsGene A/S
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN
    Publication number: 20130303459
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 14, 2013
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20130267464
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 10, 2013
    Applicant: NsGene A/S
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • IMPLANTABLE CELL DEVICE WITH SUPPORTIVE AND RADIAL DIFFUSIVE SCAFFOLDING
    Publication number: 20130261543
    Abstract: According to an embodiment of the invention, an implantable cell device is disclosed. The device includes a membrane defining and enclosing a chamber; a distance means, within the chamber, for reducing diffusion distance for a biologically active factor to across the membrane; and a support means, within the chamber, for increasing cell support surface area per unit volume of the chamber for distributing cells.
    Type: Application
    Filed: September 27, 2011
    Publication date: October 3, 2013
    Applicant: NsGene A/S
    Inventors: Lars Ulrik Wahlberg, Jens Tornøe
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 8404642
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: March 26, 2013
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 8334264
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 18, 2012
    Assignee: NsGenee A/S
    Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN
    Publication number: 20120108518
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Application
    Filed: October 3, 2011
    Publication date: May 3, 2012
    Applicant: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY
    Publication number: 20120027847
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Application
    Filed: January 21, 2010
    Publication date: February 2, 2012
    Applicant: NS GENE A/AS
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • EXPRESSION OF NEUROPEPTIDES IN MAMMALIAN CELLS
    Publication number: 20120021039
    Abstract: The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference.
    Type: Application
    Filed: January 21, 2010
    Publication date: January 26, 2012
    Applicant: NsGene A/S
    Inventors: Philip Kusk, Lars Ulrik Wahlberg, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20110112035
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 12, 2011
    Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Method And System Of Radio Communication
    Publication number: 20090325577
    Abstract: The present invention relates to handover in a communications system, and more especially it relates cell change using Iu-interface dependent neighbor-cell lists, particularly in a Universal Mobile Telecommunications System, UMTS or WCDMA system.
    Type: Application
    Filed: March 23, 2005
    Publication date: December 31, 2009
    Applicant: TELEFONAKTIEBOLAGET LM ERICSSON (PUBL)
    Inventors: Ros-Marie Furtenback, Ulrik Wahlberg